Christopher Koller, MD

Christopher Koller, M.D. is an Assistant Professor of Urology at the Hackensack Meridian School of Medicine (HMSOM) and a Director of Urologic Oncology at the HMH Clifton Health and Wellness Center.

He graduated with academic distinction from The University of North Carolina at Chapel Hill where he also received his medical degree. He completed his residency in Urology at Tulane University Medical Center where he was the chief resident during his final year of training. Dr. Koller then pursued additional fellowship training in Urologic Oncology at the National Cancer Institute (NCI) / National Institute of Health (NIH) in Bethesda, Maryland. He is an inducted member of the Society of Urologic Oncology (SUO) and the American Society of Clinical Oncology (ASCO).

As urologic oncologist he specializes in the diagnosis and treatment of cancers of the prostate, kidney, bladder, and rarer urologic malignancies such as testicular, penile, and adrenal cancers. 

His clinical interests include prostate cancer (including prostate MRI, MRI-ultrasound fusion biopsy and High-Intensity Focused Ultrasound (HIFU), bladder cancer (including blue-light cystoscopy and continent/incontinent urinary diversion), kidney cancer, testis cancer, adrenal cancer, ureteral cancer, robotic surgery with the DaVinci system (including prostatectomy, cystectomy, partial nephrectomy, and adrenalectomy). 

Dr. Koller is involved in various clinical trials and research efforts focusing on cancer of the prostate, bladder, and kidneys. He has published numerous original research articles in peer-reviewed journals, including Urologic Oncology, Urology, The Journal of Sexual Medicine, and New England Journal of Medicine – Artificial Intelligence. 

His research interests include multiparametric magnetic resonance imaging of the prostate  and its role in prostate cancer management & active surveillance, focal prostate ablation. He also functions as a co-Principle Investigator for cooperative group, investigator-initiated, and industry-sponsored clinical trials at the John Theuer Cancer Center part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University.